Key result
Compound 9, a novel pyrrolidin-2-one derivative, displayed antiarrhythmic activity in epinephrine-induced arrhythmia in rats with an ED50 of 5.0 mg/kg (3.13-7.99).
Effect estimate: ED50 5.0 mg/kg (95% CI 3.13-7.99)
A novel pyrrolidin-2-one derivative (compound 9) demonstrates α1-adrenoceptor antagonism and antiarrhythmic activity in a rat model of epinephrine-induced arrhythmia.
No takes yet. Share an insight, caveat, or question.
Pyrrolidin-2-one derivatives merit further preclinical testing; leaves open any clinical antiarrhythmic role.
Zaręba et al. (2015) studied Epinephrine-induced arrhythmia. Compound 9 (1-{4-[4-(2-methoxy-5-chlorophenyl)-piperazin-1-yl]-methyl}-pyrrolidin-2-one) was evaluated on Antiarrhythmic activity (ED50 5.0 mg/kg, 95% CI 3.13-7.99). Compound 9, a novel pyrrolidin-2-one derivative, displayed antiarrhythmic activity in epinephrine-induced arrhythmia in rats with an ED50 of 5.0 mg/kg (3.13-7.99).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: